Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- 60% Rule Applied to 5 APIs in December Generic Listing
December 14, 2012
- Mr Sato of PFSB Stresses Need for MAH to Strengthen Ties, Communications with Overseas Drug Substance Manufacturers: PDA Japan Annual Meeting
December 14, 2012
- Strategy Council Proposes Revamped Framework to Oversee Entire Life Innovation Budgets
December 12, 2012
- PMDA Taking Public Comments on Proposed Revisions of the Japanese Pharmacopoeia
December 12, 2012
- Generic Drug Use Rising at DPC Hospitals: MHLW
December 11, 2012
- MHLW Puzzled at “Opaque” GRU Recommendation after Project Screening
December 10, 2012
- Long-Listed Products Not Granted Premium Should Be Exempted from New Rule: FPMAJ’s Kamoya
December 10, 2012
- MHLW Proposes Salary Survey with Employees of Pharmacies
December 10, 2012
- CSIMC Nixes Industry’s Call for “Hold” on Further Price Cuts on Long-Listed Drugs
December 6, 2012
- Japan “Not Ready” for Reference Price System at the Present Time: Prof. Sakamaki of Meijo University
December 6, 2012
- CSIMC Subcommittee Agrees on Introduction of New Price-Cut Rule for Long-Listed Products
December 6, 2012
- MHLW Asks to Revise Precautions Section of Package Inserts for Poteligeo, Telavic
December 6, 2012
- PFSB to Initiate Epidemiological Study of Vaccination and Sudden Infant Death
December 5, 2012
- PAFSC’s 1st Committee on New Drugs Recommends Orphan Drug Designation for 2 Products Including Kyowa Kirin’s Cinacalcet
December 4, 2012
- 3 Products Including Daiichi Sankyo’s Calblock Classified as Category I
December 4, 2012
- PAFSC’s 1st Committee Recommends Approval for Factor Xa Inhibitor Apixaban
December 3, 2012
- MHLW to Conduct Field Study for Japanese Version of “Compassionate Use” System
December 3, 2012
- Price Agreement Rates for JPWA, NPhA Member Companies Just 11% at End of September: Distribution Council
December 3, 2012
- Price Agreement Rate at 43.5% in September; Down 3.2 Points from 2 Years Ago: MHLW Survey
December 3, 2012
- 6 APIs Including Taiho’s Aloxi IV Infusion Bag Added to NHI Price List
December 3, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…